MentionFox
Home › Executive changes › Vertex Pharmaceuticals Inc / Ma
Leadership changes · SEC Form 8-K, Item 5.02

Vertex Pharmaceuticals Inc / Ma executive changes

Every leadership change Vertex Pharmaceuticals Inc / Ma reported to the SEC under Item 5.02: who left, who was appointed, to what role and from when, quoted from each filing.

Filings2
Appointments named1
Departures named1
Latest filing2026-09-01

Vertex Pharmaceuticals Inc / Ma filed 2 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-09-01. Between them they name 2 people, with 1 appointment and 1 departure. Each change below is quoted from the filing and linked to it.

Every change, newest first

Filed 2026-09-01 · 8-K

Appointed: Jonathan Poole, Chief Financial Officer, effective 2027-01-01

On August 27, 2026, Vertex Pharmaceuticals Incorporated (the "Company") appointed Jonathan Poole as Executive Vice President and Chief Financial Officer of the Company, effective January 1, 2027 (the "Effective Date").
Filed 2026-04-29 · 8-K

Departing: Suketu Upadhyay, Director

On April 28, 2026, Suketu Upadhyay informed the board of directors (the "Board") of Vertex Pharmaceuticals Incorporated (the "Company") of his decision not to stand for re-election as a director of the Company at the Company's 2026 annual meeting of shareholders (the "2026 Annual Meeting").
Hiring for a seat like this?

Find people with the same kind of experience as the Chief Financial Officer at Vertex Pharmaceuticals Inc / Ma, with the record behind each one.

Find candidates like Chief Financial Officer at Vertex Pharmaceuticals Inc / Ma
Selling to Vertex Pharmaceuticals Inc / Ma?

New leaders review vendors and budgets in their first months. Get an alert the next time Vertex Pharmaceuticals Inc / Ma is in the news or changes leadership.

Get an alert when Vertex Pharmaceuticals Inc / Ma changes leadership

Tools for this story

Each opens in a new tab, filled in for Vertex Pharmaceuticals Inc / Ma. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/vertex-pharmaceuticals-inc-ma
Last updated 2026-09-27
Primary record: SEC filing 1 · SEC filing 2
Vertex Pharmaceuticals Inc / Ma (VRTX) executive changes: Jonathan Poole appointed, Chief Financial Officer. MentionFox, 2026-09-27. https://mentionfox.com/executive-changes/vertex-pharmaceuticals-inc-ma